Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report

Enfortumab vedotin (EV) is an antibody-drug conjugate and a promising agent for metastatic urothelial carcinoma (mUC). However, evaluations in end-stage renal disease patients undergoing hemodialysis are unreported. Here, we report such a case. A 74-year-old woman with mUC, on hemodialysis for compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Isoda, Bunpei, Shiga, Masanobu, Kandori, Shuya, Nagumo, Yoshiyuki, Yoshino, Takayuki, Ikeda, Atsushi, Kawahara, Takashi, Kimura, Tomokazu, Negoro, Hiromitsu, Hoshi, Akio, Mathis, Bryan J., Nishiyama, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294212/
https://www.ncbi.nlm.nih.gov/pubmed/37384209
http://dx.doi.org/10.1159/000530780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294212/
https://www.ncbi.nlm.nih.gov/pubmed/37384209
http://dx.doi.org/10.1159/000530780

Ejemplares similares